title: Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
abstract: OBJECTIVE
  Limited data suggest that germline BRCA1 mutations are associated with occult primary ovarian insufficiency and that BRCA1 and BRCA2 mutation carriers might have earlier natural menopause (NM) than their noncarrier relatives.
  
  
  METHODS
  Eligible women were mutation carriers and noncarriers from families segregating a BRCA1 or BRCA2 mutation. Data were self-reported using uniform questionnaires at cohort entry and every 3 years thereafter. NM was defined as the cessation of menses for 12 months without another cause. Cox proportional hazards analysis modeled time from birth to NM, adjusting for multiple potential confounders. Analysis time was censored at the earliest of the following: last follow-up, bilateral oophorectomy, hysterectomy, commencement of hormone therapy, insertion of intrauterine device, or any cancer diagnosis. Hazard ratios (HRs) were estimated as a measure of how likely mutation carriers are, relative to noncarriers, to reach NM at a given age.
  
  
  RESULTS
  A total of 1,840 women were eligible for analysis. Overall only 19% reached NM. A lower proportion of BRCA1 and BRCA2 mutation carriers reached NM compared with noncarriers. Conversely, a higher proportion of mutation carriers were censored at cancer diagnosis or oophorectomy than noncarriers. The adjusted HR estimates for NM were 1.03 (95% CI, 0.75 to 1.40; P = .9) for 445 BRCA1 mutation carriers and 559 noncarrier relatives and 1.01 (95% CI, 0.71 to 1.42; P = .9) for 374 BRCA2 mutation carriers and 462 noncarrier relatives.
  
  
  CONCLUSIONS
  We found no evidence that BRCA1 and BRCA2 mutation carriers are at higher risk of NM at a given age than their noncarrier relatives.
authors.affiliation: Ian M. Collins, Sue Anne McLachlan, Prue Weideman, Kate E. Birch, and Kelly-Anne Phillips, Peter MacCallum Cancer Centre; Ian M. Collins, Roger L. Milne, Sue Anne McLachlan, Martha Hickey, John L. Hopper, and Kelly-Anne Phillips, University of Melbourne; Sue Anne McLachlan, St Vincent's Hospital; Martha Hickey, Royal Women's Hospital, Parkville, Melbourne; Michael Friedlander, Prince of Wales Hospital, Sydney, Australia; and John L. Hopper, Seoul National University, Seoul, Republic of Korea.
authors.forename: Ian M
authors.initials: IM
authors.lastname: Collins
authors.forename: Roger L
authors.initials: RL
authors.lastname: Milne
authors.forename: Sue Anne
authors.initials: SA
authors.lastname: McLachlan
authors.forename: Michael
authors.initials: M
authors.lastname: Friedlander
authors.forename: Martha
authors.initials: M
authors.lastname: Hickey
authors.forename: Prue C
authors.initials: PC
authors.lastname: Weideman
authors.forename: Kate E
authors.initials: KE
authors.lastname: Birch
authors.forename: John L
authors.initials: JL
authors.lastname: Hopper
authors.forename: Kelly-Anne
authors.initials: KA
authors.lastname: Phillips
mesh_terms: D000328:Adult; D015331:Cohort Studies; D005260:Female; D005582:Foundations; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006579:Heterozygote; D006801:Humans; D008593:Menopause / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation; D016016:Proportional Hazards Models